However, although the targeting of both BRAF and MEK has been used as a standard treatment approach for patients with melanoma harbouring BRAF V600 mutations the challenge still remains because of the variable patient responses to that combination and of drug resistance111–113. Here, MAP2K7 is linked to melanoma.